Fluoxetine and Buspirone Combination in Anorexia Nervosa
The combination of fluoxetine and buspirone is not appropriate for treating anorexia nervosa, as neither medication has demonstrated efficacy in this condition, and the current evidence-based standard of care prioritizes eating disorder-focused psychotherapy without pharmacotherapy.
Evidence-Based Treatment for Anorexia Nervosa
The 2023 APA guidelines are unequivocal: adults with anorexia nervosa should be treated with eating disorder-focused psychotherapy (1B recommendation), which includes normalizing eating behaviors, restoring weight, and addressing psychological aspects like fear of weight gain and body image disturbance 1. Notably absent from these guidelines is any recommendation for pharmacotherapy—including fluoxetine, buspirone, or their combination—in the treatment of anorexia nervosa.
Why Fluoxetine Fails in Anorexia Nervosa
The evidence against fluoxetine in anorexia nervosa is particularly strong:
The landmark 2006 JAMA trial found no benefit from fluoxetine versus placebo in weight-restored patients with anorexia nervosa 2. Only 26.5% of fluoxetine patients versus 31.5% of placebo patients maintained recovery at 52 weeks (p=0.57), with no difference in time-to-relapse (hazard ratio 1.12, p=0.64).
A 2025 secondary analysis suggests fluoxetine may only benefit the subset of weight-restored patients with moderate-to-severe depression (BDI >20) 3. However, this represents a small subgroup and requires replication before clinical application.
The 2018 systematic review concluded that SSRIs lack efficacy during acute treatment of anorexia nervosa and should not be used as sole therapy 4.
Why Buspirone Is Not Indicated
Buspirone has no evidence base for anorexia nervosa. The only eating disorder study identified examined buspirone in bulimia nervosa, not anorexia nervosa 5. The APA guidelines specifically recommend fluoxetine 60 mg daily for bulimia nervosa 1, but make no mention of buspirone for any eating disorder.
Critical Safety Considerations
If medications are being considered despite lack of efficacy evidence:
- ECG monitoring is mandatory in patients with restrictive eating disorders before starting any medication that may prolong QTc intervals 1
- Buspirone carries significant drug interaction risks, particularly with serotonergic agents, requiring caution with any concurrent antidepressant use 6
- Serotonin syndrome risk exists when combining buspirone with SSRIs like fluoxetine, requiring immediate discontinuation if symptoms emerge 6
The Correct Treatment Algorithm
For adults with anorexia nervosa:
Initiate eating disorder-focused psychotherapy as first-line treatment (CBT-ED or similar modalities that address eating behaviors, weight restoration, and psychological factors) 1
Set individualized weight restoration goals with weekly weight gain targets 1
Coordinate multidisciplinary care incorporating medical, psychiatric, psychological, and nutritional expertise 1
Consider fluoxetine only in weight-restored patients who remain significantly depressed (BDI >20) after nutritional rehabilitation, based on emerging evidence 3—but recognize this is not guideline-supported
Avoid buspirone entirely for anorexia nervosa given complete absence of supporting evidence
Common Pitfalls to Avoid
- Do not prescribe antidepressants to underweight patients expecting improvement in eating disorder symptoms—the evidence shows no benefit 2, 4, 7
- Do not use medications as monotherapy—psychotherapy must be the foundation of treatment 4
- Do not assume depression treatment will improve anorexia nervosa—these are distinct conditions requiring targeted interventions
- Do not combine buspirone with fluoxetine without compelling psychiatric indications beyond anorexia nervosa, given interaction risks 6
The evidence is clear: psychotherapy, not pharmacotherapy, is the cornerstone of anorexia nervosa treatment, and neither fluoxetine nor buspirone—alone or in combination—has demonstrated benefit for improving core anorexia nervosa symptoms or preventing relapse in the general population with this disorder.